Retatrutide trials report fewer sleep apnea episodes alongside weight loss
The triple agonist is being tested in obstructive sleep apnea, a setting where tirzepatide already holds an FDA indication.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 26 12:21 ETSource: Daijiworld
The wire
- 01Clinical trial results reported for Eli Lilly's retatrutide describe reductions in sleep apnea episodes together with weight loss.
- 02Sleep apnea is becoming a competitive endpoint for incretin drugs, relevant to clinicians weighing CPAP alternatives for patients with obesity.
- 03Specific apnea-hypopnea index changes, doses, sample size and trial phase are not detailed in the report; full publication would be needed to judge effect size.
From the source
Read at daijiworld.comRetatrutide cuts sleep apnea episodes in clinical trials, promotes weight loss
